Physician profile
Michael S Levine
NPI 1356415285
$1,902.02
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $196 · 2021: $51.16 · 2022: $139 · 2023: $239 · 2024: $476 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $358.52 | 2019-2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $236.02 | 2022-2025 | Oxlumo, Amvuttra |
| Akebia Therapeutics INC | $162.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $153.08 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $144.31 | 2021-2023 | Breztri, Fasenra |
| Csl Behring | $138.98 | 2021-2024 | Kcentra |
| Eisai INC. | $123.06 | 2024 | |
| United Therapeutics Corporation | $120.85 | 2024 | Tyvaso |
| Janssen Pharmaceuticals, INC | $103.76 | 2019 | |
| Novo Nordisk INC | $103.50 | 2020 | |
| Abbvie INC. | $79.38 | 2022-2024 | |
| Allergan, INC. | $72.41 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.26 | 2022 | |
| Opko Pharmaceuticals, LLC | $22.57 | 2019 | |
| Amarin Pharma, INC. | $20.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2022 | |
| Lilly USA, LLC | $14.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.